KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.

Marita Prohn, Carolyn R Cho, Anders Viberg, Kevin Dykstra, Casey Davis, Philip Sabato, Julie Stone, Cyrus Badshah, Yoshihiko Murata, Randi Leavitt, Craig Fancourt, Sreeraj Macha

Clin Pharmacol Ther 111(2) 485-495

PMID34674258
PMCID-
DOI10.1002/cpt.2456
发表日期2021-10-21
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

The cytomegalovirus (CMV) viral terminase inhibitor letermovir is approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplantation recipients. In a phase III trial (NCT02137772), letermovir significantly reduced clinically significant CMV infection (CS-CMVi) rate vs. placebo through Week 24 (primary end point) and Week 14 (secondary end point) post transplantation. Here, exposure-response relationships were investigated using efficacy and selected safety end points from the phase III trial to inform the proposed clinical dose. Post hoc exposure estimates were derived from a population pharmacokinetic model. No significant exposure dependencies were found for CS-CMVi through Week 24 or Week 14 among letermovir-treated participants. Evaluated covariates had no impact on exposure-efficacy relationships and letermovir plasma exposure did not affect time of CS-CMVi onset. There was no dependence between adverse event incidence and letermovir exposure. These results support current dosing recommendations in several countries and regions, including the United States and European Union.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。